盈康生命(300143) - 2022 Q1 - 季度财报

Financial Performance - The company reported total revenue of CNY 267,547,194.29 for Q1 2022, representing a 10.72% increase compared to CNY 241,650,934.90 in the same period last year[4] - Net profit attributable to shareholders was CNY 24,105,210.83, up 30.56% from CNY 18,462,593.64 in the previous year[4] - The net profit after deducting non-recurring gains and losses reached CNY 25,308,886.27, a significant increase of 359.61% compared to a loss of CNY 9,748,848.60 in the same period last year[4] - Total operating revenue for the current period reached ¥267,547,194.29, an increase of 10.7% compared to ¥241,650,934.90 in the previous period[48] - Net profit for the current period was ¥26,705,857.97, a 27.4% increase from ¥20,984,638.64 in the previous period[48] - The total profit for the current period was ¥33,514,053.58, compared to ¥27,391,487.46 in the previous period, indicating a growth of 22.5%[48] Cash Flow and Assets - The company's cash flow from operating activities was CNY 35,865,963.18, down 37.80% from CNY 57,666,133.51 in the previous year, primarily due to increased payments for goods and services[4] - Cash flow from operating activities was ¥295,614,194.14, a slight decrease from ¥298,064,261.28 in the previous period[51] - The net cash flow from operating activities for Q1 2022 was ¥35,865,963.18, a decrease of 37.8% compared to ¥57,666,133.51 in Q1 2021[52] - The total cash and cash equivalents at the end of Q1 2022 reached ¥681,641,103.56, up from ¥313,104,647.99 at the end of Q1 2021[53] - Total assets at the end of the reporting period were CNY 2,520,945,935.19, reflecting a 1.94% increase from CNY 2,473,064,924.99 at the end of the previous year[5] - Current assets totaled CNY 944,025,519.52, up from CNY 897,947,747.02, indicating an increase of about 5.14%[44] Investments and Acquisitions - The company completed the acquisition of Suzhou Guangci Tumor Hospital, which became a wholly-owned subsidiary, leading to adjustments in financial reporting[5] - The company has initiated a stock repurchase plan, indicating a commitment to enhancing shareholder value[41] - The company has repurchased a total of 2,509,317 shares, accounting for 0.39% of the total share capital, with a total expenditure of RMB 50,000,708.48, at prices ranging from RMB 15.30 to RMB 21.81 per share[34] Research and Development - The company aims to establish a comprehensive research and development system for tumor treatment, diagnosis, and prevention, with a focus on long-term technological advancements[11] - Research and development expenses decreased to ¥4,916,338.15 from ¥5,723,473.58, a reduction of 14.1%[48] User Growth and Services - The company added 118,000 new users during the reporting period, with online transaction volume reaching 205,000 orders, and the online registration rate increased by 130% quarter-on-quarter[13] - Medical equipment service revenue amounted to 4.58 million, representing a year-on-year increase of 353%[15] - The company achieved zero infections in hospitals while increasing medical user service volume compared to the same period last year[20] Talent and Human Resources - The company recruited a total of 14 new master's and doctoral talents, with the proportion of master's and doctoral doctors increasing to 12.2% from 6.5% in June 2021[21] - The company has established a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and core team members[35] Corporate Social Responsibility - The company donated a set of advanced medical equipment to support public health initiatives in Tibet, enhancing local healthcare services and training for young medical professionals[32] - The company aims to enhance its brand influence and social responsibility through its donation initiatives, contributing to sustainable development[32] - The company has committed to improving the accessibility of high-quality medical resources, aligning with its corporate vision of "providing lifelong health for everyone"[37]